Veliparib (ABT-888) is still under ongoing clinical trials and is being evaluated for efficacy in combined treatment with platinum-based chemotherapy for HER2-negative metastatic/locally advanced, gBRCA-mutated breast cancer [58]. This evidence concerns the gene ERBB2 and breast cancer.